Ticker Details
Viking Therapeutics, Inc. Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
IPO Date:	April 29, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.95B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.56 | 3.76%
Avg Daily Range (30 D):	$0.82 | 2.29%
Avg Daily Range (90 D):	$0.89 | 2.63%

Institutional Daily Volume
Avg Daily Volume:	1.88M
Avg Daily Volume (30 D):	1.6M
Avg Daily Volume (90 D):	1.97M

Trade Size
Avg Trade Size (Sh.):	112
Avg Trade Size (Sh.) (30 D):	63
Avg Trade Size (Sh.) (90 D):	70

Institutional Trades
Total Institutional Trades:	5,465
Avg Institutional Trade:	$2.77M
Avg Institutional Trade (30 D):	$3.98M
Avg Institutional Trade (90 D):	$3.42M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.52M
Avg Closing Trade (30 D):	$7.79M
Avg Closing Trade (90 D):	$8.13M
Avg Closing Volume:	247.38K

News

Aug 8, 2026 @ 7:30 PM Better GLP-1 Stock to Buy: Eli Lilly or Viking The... Source: Prosper Junior Bakiny

Aug 6, 2026 @ 2:21 PM Viking Therapeutics Declined in July, and why its ... Source: Lee Samaha

Jul 30, 2026 @ 10:30 PM Vertex Just Paid $10 Billion for Crinetics. Here's... Source: Prosper Junior Bakiny

Jul 18, 2026 @ 1:30 PM Should You Buy Viking Therapeutics Stock on the Di... Source: Lee Samaha

Jul 17, 2026 @ 1:31 AM Kuehn Law Encourages Investors of Viking Therapeut... Source: Kuehn Law, Pllc

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-4.67	$-1.1	$-1.37
Diluted EPS	$-4.67	$-1.1	$-1.37
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-534.8M	$-128.02M	$-158.33M
Operating Income / Loss	$-560.02M	$-132.6M	$-164.13M
Cost of Revenue
Net Cash Flow	$92.06M
PE Ratio